What is the Historical Analysis of the Chronic Cough Market Size?
The chronic cough market has seen considerable growth due to a variety of factors.
•The market size for chronic cough has experienced robust growth in the past few years. Predictions indicate an increase from $8.22 billion in 2024 to $8.9 billion in 2025, signifying a compound annual growth rate (CAGR) of 8.3%.
Factors fueling this growth in the historic period include the high incidence of underlying respiratory conditions, the influence of environmental factors and air pollution, the use of tobacco and smoking, instances of respiratory infections, and prevalance of allergies and environmental sensitivities.
What is the Forecasted Growth of the Chronic Cough Market Size?
The chronic cough market is expected to maintain its strong growth trajectory in upcoming years.
• The market for chronic cough is predicted to witness substantial expansion in the coming years. The market is projected to reach $12.89 billion in 2029, growing at a compound annual growth rate (CAGR) of 9.7%.
The surge in this forecast period can be linked to the development of new therapies targeting specific pathways, enhanced comprehension of reflux-related cough, worldwide initiatives for smoking cessation, and policies regarding environmental and occupational health. Noteworthy trends during this forecast period comprise advancements in diagnostic technologies, patient-focused strategies, innovative treatments for neurogenic cough, the use of telehealth in managing chronic cough, and research on central sensitization.
What Key Factors and Trends are Driving the Growth of the Chronic Cough Market?
Increasing instances of cough are likely to accelerate the expansion of the chronic cough market. Cough serves as a reflex action, often triggered by irritation, mucus or foreign substances, facilitating airway clearance by forcibly expelling air from the lungs. A cough lasting at least eight weeks is defined as chronic. Thus, an upsurge in cough cases elevates the incidences of chronic cough. For instance, as reported by Florida Health, a healthcare department based in the US, in March 2022, a total of 80 patients in the US were identified in 2021 with incidence rates of 41.0 and 1.4 per 100,000 years, respectively. In 2023, there were 28 reported pertussis cases across 13 countries. Furthermore, data from Statens Serum Institut, a Denmark-based disease surveillance department, in March 2022 revealed a 41% increment in pertussis cases from November 2022 to April 2023, in contrast to the numbers from November 2021 to April 2022 in Denmark. Consequently, increasing cough prevalence contributes to the growth of the chronic cough market.
What are the Market Segments in the Chronic Cough Market?
The chronic cough market covered in this report is segmented –
1) By Drug Class: Antihistamines, Corticosteroids, Decongestants, Combination Drug, Antibiotics, Acid Blockers, Other Drug Classes
2) By Route Of Administration: Oral, Inhalational, Injectable, Other Route Of Administrations
3) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
Subsegments:
1) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines
2) By Corticosteroids: Inhaled Corticosteroids, Systemic Corticosteroids
3) By Decongestants: Oral Decongestants, Nasal Decongestants
4) By Combination Drug: Antihistamine And Decongestant Combinations, Cough Suppressant And Expectorant Combinations
5) By Antibiotics: Macrolides, Penicillins, Cephalosporins
6) By Acid Blockers: Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists
7) By Other Drug Classes: Mucolytics, Cough Suppressants, Herbal Remedies
Pre-Book The Chronic Cough Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends are Shaping the Chronic Cough Market?
Leading businesses in the chronic cough market are focusing on developing novel products like biosimilars to solidify their footing in the industry. Biosimilars are employed in treating conditions such as cancer, autoimmune disorders, and diabetes, offering an economical alternative to current biologics. For instance, in July 2024, Sandoz, a reputed Pharmaceutical firm from Switzerland, introduced its biosimilar product, Pyzchiva (ustekinumab) throughout Europe targeting persistent inflammatory diseases like plaque psoriasis, psoriatic arthritis, and Crohn's disease. This biosimilar stands out, being the first in Europe to offer all reference medicine strengths, including the starting dosage for Crohn's disease. By collaborating with Samsung Bioepis, Sandoz aims to increase accessibility to effective therapeutic options for the millions impacted by these diseases. The introduction mirrors Sandoz's pledged dedication towards providing budget-friendly healthcare solutions and enhancing patients' quality of life across Europe.
Who Are the Key Players in the Chronic Cough Market?
Major companies operating in the chronic cough market include:
• Tris Pharma Inc.
• Pfizer Inc.
• Johnson & Johnson Co
• Bayer AG
• Novartis AG
• Sanofi SA
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Glaxo SmithKline Plc
• Merck KGaA
• Reckitt Benckiser Group plc
• Glenmark Pharmaceuticals Ltd
• Teva Pharmaceutical Industries Ltd.
• Mylan NV
• Aurobindo Pharma Ltd.
• Cipla Limited
• Apotex Inc.
• Hikma Pharmaceuticals Plc
• Amneal Pharmaceuticals LLC
• Mount Sinai Health System
• Biocon Ltd.
• BELLUS Health Inc.
• Trevi Therapeutics Inc.
• Sun Pharmaceutical Industries Ltd.
• NeRRe Therapeutics Ltd.
What are the Regional Insights into the Chronic Cough Market?
North America was the largest region in the chronic cough market in 2024. The regions covered in the chronic cough market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
